期刊文献+

复方丹参滴丸对I/R大鼠心脏表面血流量和心肌损伤的改善作用 被引量:5

Pre-treatment with Cardiotonic Pills Attenuates Ischemia-reperfusion-induced Myocardial Blood Flow and Myocardial Injury in Rats
下载PDF
导出
摘要 目的:探讨复方丹参滴丸(CP)预给药对缺血30min再灌注24h后大鼠心肌损伤的改善作用。方法:雄性SD大鼠60只,分为模型组(12只)、假手术组(12只)、给药(0.1g/Kg、0.4g/Kg、0.8g/Kg)组(各12只),结扎模型组大鼠冠状动脉左前降支30min,解除结扎再灌注24h,建立缺血再灌注(I/R)模型。假手术组只穿线不结扎。给药各组在手术前90min分别一次性灌胃给予CP(0.1g/Kg、0.4g/Kg和0.8g/Kg)后,行模型组相同手术和操作。各组大鼠均采用激光多普勒血流灌注成像仪测定心脏表面血流量;TTC染色法测定心肌梗死面积;TUNEL染色法检测心肌凋亡细胞。结果:模型组大鼠心脏表面血流量明显降低、心肌梗死面积增加、凋亡心肌细胞数增多。三个CP剂量组都能增加心脏表面血流量、减少心肌梗死面积、抑制心肌细胞凋亡。结论:CP具有改善I/R24h大鼠心脏血流量和心肌损伤的作用。 Objective:To investigate the effect of cardiotonic pills(CP) on myocardial damage during ischemia-reperfusion(I/R) injury.Method:60 Sprague-Dawley(SD) rats were used and divided into 5 groups for evaluating various parameters of concern.Myocardial I/R model was induced by occlusion left anterior descending coronary artery for 30 min and reperfusion for 24 hours,which were subjected to I/R with or without pre-treatment with CP(0.1 g/Kg,0.4 g/Kg or 0.8 g/Kg).Myocardial blood flow(MBF) was monitored by using the Laser Doppler imaging technique.Tthe infarct size was detected by TTC staining,and the apoptotic cells were analyzed by TUNEL staining.Results:Pre-treatment with CP significantly alleviated I/R induced disorders in myocardial microvasculature,manifested as the reduction of MBF.CP also decreased myocardial infarct size and myocardial apoptotic cells at 24 h after reperfusion.Conclusion:Pre-treatment with CP could attenuate I/R-induced myocardial blood flow and myocardial injury.
出处 《微循环学杂志》 2012年第2期21-23,30,F0003,I0001,共6页 Chinese Journal of Microcirculation
基金 国家科技部新药创新项目(2008ZX09401)
关键词 复方丹参滴丸 缺血再灌注 心脏血流量 心肌凋亡 心肌梗死 大鼠 Cardiotonic pills Ischemia-reperfusion Myocardial blood flow Myocardial apoptosis Myocardial infarction Rat
  • 相关文献

参考文献11

  • 1Liem DA,Honda HM,Zhang J,et al.Past and present course of cardioprotection against ischemia-reperfusion injury[J].J Appl Physiol,2007,103(6):2129-2136.
  • 2Boden WE,O'Rourke RA,Teo KK,et al.Optimal medical therapy with or without PCI for stable coronary disease[J].N Engl J Med,2007,356(15):1503-1516.
  • 3Das M,Gherghiceanu M,Lekli I,et al.Essential role of lipid raft in ischemic preconditioning[J].Cell Physiol Biochem,2008,21(4):325-334.
  • 4范宝晶,赵学忠.复方丹参滴丸对急性冠脉综合征患者经皮冠脉介入治疗后心肌微循环的研究[J].中国新药杂志,2009,18(10):903-906. 被引量:4
  • 5Zhao N,Liu YY,Wang F,et al.Cardiotonic pills,a compound Chinese medicine,protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats[J].Am J Physiol Heart Circ Physiol,2010,298(4):H1166-H1176.
  • 6刘育英 卫晓红 赵娜等.复方丹参滴丸及其主要成分对心脏缺血再灌注引起的大鼠微循环障碍和心肌损伤的保护作用.微循环学杂志,2010,20(2):62-62.
  • 7Hishikari K,Suzuki J,Ogawa M,et al.Pharmacological activation of the prostaglandin E2receptor EP4improves cardiac function after myocardial ischaemia/reperfusion injury[J].Cardiovasc Res,2009,81(1):123-132.
  • 8Mackman N.The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury[J].Semin Vasc Med,2003,3(2):193-198.
  • 9Xie JR,Yu LN.Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion[J].Acta Anaesthesiol Scand,2007,51(7):909-913.
  • 10Lay IS,Hsieh CC,Chiu JH,et al.Salvianolic acid B enhances in vitro angiogenesis and improves skin flap survival in SpragueDawley rats[J].J Surg Res,2003,115(2):279-285.

二级参考文献17

  • 1孙迪,王延倧.复方丹参滴丸治疗冠心病、心绞痛急性发作临床观察[J].青岛医药卫生,2003,35(4):281-282. 被引量:7
  • 2声诺维临床研究协作组.声诺维在心内膜缘显像及心肌灌注中的效果评价[J].中华内科杂志,2004,43(11):824-827. 被引量:13
  • 3MICHELA KB, YUSWF S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rate? A quantitative overview (meta analysis) of the randomized clinical trials[ J]. Circulation, 1995, 91(2) : 476 -485.
  • 4KENNER MD, ZAJAC E J, KONDOS GT, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up [ J ]. Am J Cardiol, 1995, 76(12) : 861 -868.
  • 5MORISHIMA I, SONE T, MOKUNO S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty[ J]. Am Heart J, 1995, 130(2) : 239 -243.
  • 6KLONER RA, GANOTE CE, JENNINGS RB. The no-reflow phenomenon after temporary coronary occlusion in the dog[ J]. J Clin Invest, 1974, 54(6): 1496-1508.
  • 7GIBSON CM. Has my patient achieved adequate myocardial reperfusion? [ J ]. Circulation, 2003, 108 (5) : 504 - 507.
  • 8ITO H, MARUYAMA A, IWAKURA K, et al. Clinical implications of the " no-reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction [ J ]. Circulation, 1996, 93 ( 2 ) : 223 - 228.
  • 9ITO H, IWAKURA K. Assessing the relation between coronary reflow and myocardial reflow [ J ]. Am J Cardiol, 1998, 81 (12A) : 8G - 12G.
  • 10THEROUX P. Angiographic and clinical progression in unstable angina pectoris from clinical observalion to clinical trial[ J ]. Circulation, 1995, 91 (9) : 2995 - 2298.

共引文献4

同被引文献95

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部